Table 1.

Changes in insulin dose, mean BG, HbA_1c, and stimulated C-peptide in type 1 diabetic patients with (C-peptide positive) and without (C-peptide negative) residual β-cell function before (week 0) and during (week 4) 4 weeks of treatment with liraglutide or insulin alone

Treatment	C-peptide positive		C-peptide negative		C-peptide negative
	Liraglutide + insulin		Liraglutide + insulin		Insulin only
	Week 0	Week 4	Week 0	Week 4	Week 0	Week 4
Insulin dose (units/kg per day)	0.50 ± 0.06	0.31 ± 0.08*	0.72 ± 0.08	0.59 ± 0.06†	0.62 ± 0.04	0.64 ± 0.05 (NS)
Mean blood glucose (mmol/L)	6.0 ± 0.2	6.3 ± 0.3 (NS)	7.5 ± 0.4	7.7 ± 0.4 (NS)	7.5 ± 0.4	7.5 ± 0.6 (NS)
HbA1c (%)	6.6 ± 0.3	6.4 ± 0.2†	7.5 ± 0.2	7.0 ± 0.1†	7.1 ± 0.3	6.9 ± 0.2 (NS)
C-peptide (pmol/L)‡	520 ± 106	457 ± 79 (NS)	—	—	—	—

Data are means ± SE. Mean blood glucose levels are derived from continuous glucose monitoring as mean values during 3 days with identical food intake and physical activity in week 0 and week 4. NS, nonsignificant vs. week 0 in the same group.

*P < 0.001 and

†P < 0.05 vs. week 0 in the same group.

‡n = 8.